Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





Reported Tuberculosis in the United States, 2016										Related Pages
										Return to Main Menu
(PDF pdf icon[224K])
Table 9. Tuberculosis Cases and Percentages, by Multidrug Resistance (MDR)1, Origin of Birth, and Previous History of TB: United States, 1993–2016
Table 9
Year
All MDR2
Multidrug Resistant TB CasesTotal MDR3
U.S.-born MDR3
Non-U.S.–born3,4 MDRPrevious TB
No Previous TB
Previous TB
No Previous TB
Previous TB
No Previous TBEligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)
Eligible
No.
(%)1993
484
982
76
(7.7)
16,601
407
(2.5)
668
30
(4.5)
11,808
301
(2.5)
301
46
(15.3)
4,665
103
(2.2)1994
431
1,033
74
(7.2)
16,417
353
(2.2)
693
35
(5.1)
11,009
238
(2.2)
336
38
(11.3)
5,291
110
(2.1)1995
327
958
70
(7.3)
16,023
254
(1.6)
592
28
(4.7)
10,340
169
(1.6)
364
42
(11.5)
5,652
85
(1.5)1996
250
862
43
(5.0)
15,360
207
(1.3)
559
21
(3.8)
9,637
104
(1.1)
303
22
(7.3)
5,676
102
(1.8)1997
201
742
44
(5.9)
14,449
155
(1.1)
455
12
(2.6)
8,696
76
(0.9)
286
32
(11.2)
5,708
79
(1.4)1998
155
749
23
(3.1)
13,420
132
(1.0)
485
6
(1.2)
7,695
55
(0.7)
262
17
(6.5)
5,692
76
(1.3)1999
157
669
28
(4.2)
12,659
127
(1.0)
382
6
(1.6)
7,011
39
(0.6)
284
22
(7.7)
5,596
88
(1.6)2000
146
632
26
(4.1)
11,829
120
(1.0)
360
2
(0.6)
6,141
40
(0.7)
272
24
(8.8)
5,659
80
(1.4)2001
151
629
33
(5.2)
11,514
115
(1.0)
324
7
(2.2)
5,570
34
(0.6)
302
26
(8.6)
5,908
81
(1.4)2002
158
570
26
(4.6)
10,820
132
(1.2)
303
3
(1.0)
5,059
35
(0.7)
265
23
(8.7)
5,720
97
(1.7)2003
119
524
21
(4.0)
10,752
94
(0.9)
253
2
(0.8)
4,853
23
(0.5)
271
19
(7.0)
5,869
70
(1.2)2004
128
537
27
(5.0)
10,482
100
(1.0)
274
4
(1.5)
4,683
26
(0.6)
263
23
(8.7)
5,789
74
(1.3)2005
125
507
23
(4.5)
10,065
98
(1.0)
240
2
(0.8)
4,396
20
(0.5)
267
21
(7.9)
5,652
77
(1.4)2006
124
493
20
(4.1)
9,908
103
(1.0)
203
1
(0.5)
4,127
19
(0.5)
289
19
(6.6)
5,765
84
(1.5)2007
124
496
19
(3.8)
9,646
101
(1.0)
206
3
(1.5)
3,838
18
(0.5)
288
16
(5.6)
5,755
83
(1.4)2008
107
429
19
(4.4)
9,307
88
(0.9)
170
3
(1.8)
3,647
21
(0.6)
259
16
(6.2)
5,654
67
(1.2)2009
116
341
19
(5.6)
7,742
91
(1.2)
115
1
(0.9)
3,014
12
(0.4)
225
18
(8.0)
4,720
79
(1.7)2010
105
359
16
(4.5)
7,814
87
(1.1)
129
2
(1.6)
2,943
14
(0.5)
230
14
(6.1)
4,865
73
(1.5)2011
128
345
27
(7.8)
7,556
101
(1.3)
137
1
(0.7)
2,701
17
(0.6)
208
26
(12.5)
4,852
84
(1.7)2012
89
356
12
(3.4)
7,085
77
(1.1)
127
0
(0)
2,524
13
(0.5)
229
12
(5.2)
4,561
64
(1.4)2013
96
301
12
(4.0)
6,866
83
(1.2)
98
2
(2.0)
2,286
7
(0.3)
203
10
(4.9)
4,575
76
(1.7)2014
94
336
24
(7.1)
6,746
70
(1.0)
95
0
(0)
2,187
10
(0.5)
241
24
(10.0)
4,555
60
(1.3)2015
88
316
16
(5.1)
6,946
72
(1.0)
100
3
(3.0)
2,185
10
(0.5)
216
13
(6.0)
4,756
62
(1.3)2016
97
296
18
(6.1)
6,613
78
(1.2)
82
0
(0)
2,032
8
(0.4)
214
18
(8.4)
4,567
70
(1.5)1Resistance to at least isoniazid and rifampin. Isolates may be resistant to other drugs. Excludes cases with susceptibility testing not done or unknown for isoniazid and rifampin. Cases have been susceptibility tested to at least isoniazid and rifampin.2This column provides an overall total of all MDR cases, including those where previous history of TB is unknown and origin or birth is unknown.
3Excludes cases where previous history of TB is unknown and cases where origin of birth is unknown.
4Includes persons born outside the United States (including the U.S. territories).
**Note:** Data for all years updated through June 21, 2017. One non-U.S.–born case had missing information on previous TB status and was excluded from the non-U.S.–born columns.
							
					
						Page last reviewed:  November 13, 2017					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue